Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 August 2018 Photo Sonia Small
Karen Lazenby WomenofKovsies
Dr Karen Lazenby strives for a stronger, rule-based, and consistent governance structure.

A transformed University of the Free State (UFS) will be one that promotes social justice in everything it does, a university where its diverse people feel a sense of common purpose and engagement. The UFS is developing this through its Integrated Transformation Plan (ITP) introduced in January 2017. 

“The majority of the current systems and processes in student administration at the university are still manual. This lack of automation leads to inconsistencies and service failures,” says Dr Karen Lazenby. As Registrar for Systems and Administration, Dr Lazenby is responsible for ensuring a smooth and efficient student lifecycle across all three campuses. 

With the ITP, the Governance: Systems and Administration work stream strives to have a stronger, rule-based, and consistent governance structure with a single line of accountability in student administration across all faculties and relevant support departments on the three campuses. By ensuring this ease of use and access there will be an integrated student experience and greater empowerment of students.

“Our focus is on automation and self-services for students (such as the time-table, requests for additional and ad hoc exams and appeals), to ensure transparency and accessibility of rules and policies, decisions relating to admission, progression rules, awarding of qualifications and graduation and faculty and general rules,” Dr Lazenby said.  It will also entail the optimisation of PeopleSoftCampus (the Enterprise Resource Planning system).

“Through this automation, I would also like to get the university’s student administration to such a level that academic staff can focus their energy on teaching and research and student administration staff can focus more on quality assurance,” said Dr Lazenby.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept